

Introducing...

## the NEW KAPA Target Enrichment Portfolio<sup>†</sup>

Roche

# BETTER BY DESIGN

Combine Roche's 12 years of design expertise with a new and improved probe technology to achieve:


- Increased target coverage<sup>\*\*</sup>
- Superior probe fidelity<sup>\*\*</sup>
- Greater coverage uniformity<sup>\*\*†</sup>
- Fewer duplicate reads<sup>\*\*†</sup>



## Increase sequencing efficiency with new KAPA Target Enrichment<sup>\*\*†</sup>

- Design your own custom panels<sup>†</sup> with variable tiling or end-to-end probe design
- Evaluate **KAPA HyperExome**<sup>†</sup>, our efficient 43 Mb whole exome panel, which features 387 SNPs to facilitate sample-intrinsic tracking<sup>†</sup>

General sequencing metrics



The **NEW KAPA HyperExome** achieves a high % of reads-on-target, as well as highly uniform coverage—even across regions with high or low %GC<sup>‡</sup>. Prior to capture with KAPA HyperExome, libraries were prepared with KAPA HyperPrep Kits and KAPA UDI adapters using 100 ng of Covaris-sheared DNA as input. Libraries were multiplexed (8 libraries per capture), hybridized to probes for 16 hours, amplified post-capture, and sequenced on an Illumina NovaSeq sequencer (2 x 100 bp). Each bar represents 60 M high-quality trimmed reads from 16 different cell lines.

LEARN MORE AT ASHG BOOTH 701 OR VISIT [GO.ROCHE.COM/KAPA-TE](http://GO.ROCHE.COM/KAPA-TE)

<sup>\*</sup>Compared to SeqCap EZ. <sup>†</sup>Data on file. <sup>‡</sup>Product in Development. Not yet available for sale in the US.

For Research Use Only. Not for use in diagnostic procedures.

KAPA and SEQCAP are trademarks of Roche. All other product names and trademarks are the property of their respective owners.

© 2019 Roche Sequencing and Life Science. All rights reserved.